Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs MasTec Inc (MTZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs MasTec Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while MasTec Inc trades at $370 (market cap $29.47B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and MasTec Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | MTZ | |
|---|---|---|
Market Cap | $39.89B | $29.47B |
Sector | Health | Technology |
52-Week High | $491.22 | $437.51 |
52-Week Low | $278.09 | $170.24 |
Enterprise Value | $38.15B | $32.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
MasTec (MTZ) trades at $372.89, down 3.07% on the day, with a neutral technical signal and strong fundamental backdrop. The stock shows robust earnings momentum, beating estimates for three consecutive quarters, and benefits from a record $20.3 billion backlog. Recent acquisition of The Superior Group for $1.65 billion enhances its data center infrastructure capabilities, positioning the company for growth in AI-driven power demand and broadband expansion.
Outlook remains positive with 88.9% analyst buy ratings and a $479.85 consensus price target implying 28.7% upside. Key risks include execution of large acquisitions and integration challenges, while high P/E of 65.3 suggests premium valuation. Revenue growth and margin expansion from infrastructure spending trends support long-term potential, but investors should monitor debt levels and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
